| Similar Articles |
|---|
 |
The Motley Fool
July 30, 2007
Brian Lawler |
AtheroGenics Follows a New Route AtheroGenics gives more details on the path forward for its lead drug. The drugmaker is trading at a low $70 million valuation, but investors who buy into shares today shouldn't get their hopes up for the outcome.   |
The Motley Fool
March 28, 2007
Brian Lawler |
AtheroGenics Splices the Data Shares of AtheroGenics will continue to be volatile in the next couple of months as investors await the probable discontinuation of the company's partnership with AstraZeneca. |
The Motley Fool
February 26, 2007
Brian Lawler |
Waiting on AtheroGenics The results might be positive for this pharma, but don't bet on it. Investors, take note. |
The Motley Fool
March 20, 2007
Brian Lawler |
Heart Attack at AtheroGenics Shares of AtheroGenics drop after negative phase 3 trial results. |
The Motley Fool
April 24, 2007
Brian Lawler |
AtheroGenics Loses a Partner The specialty drug maker's drug-development partner bails. Waiting around for years on more clinical trial results for a drug with such unproven efficacy is not something that is a recipe for success with specialty pharma stock investing. |
The Motley Fool
October 24, 2006
Brian Lawler |
Playing the AtheroGenics Waiting Game The results of phase 3 trials for the company's atherosclerosis drug will determine AtheroGenics' future. Investors, take note. |
The Motley Fool
November 14, 2011
Brian Orelli |
Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up. |
The Motley Fool
August 30, 2005
Charly Travers |
A Drug to Make Hearts Happy? Atherogenics has a potential blockbuster in a drug that could reverse the clogging of arteries. Investors, take note. |
BusinessWeek
September 5, 2005
Gene G. Marcial |
AtheroGenics May Be A Buyout AtheroGenics is one of the more attractive acquisition candidates of Merck or Pfizer. |
The Motley Fool
March 1, 2007
Brian Lawler |
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
January 27, 2004
David Nierengarten |
Pfizer's Next Target? Esperion, swallowed by Pfizer last year, shares many similarities with Atherogenics. Investors in the latter, however, should not count on being acquired any time soon by a big pharmaceutical company. |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
The Motley Fool
July 27, 2007
Tom Taulli |
A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth. |
Pharmaceutical Executive
October 1, 2006
Rob Scott |
Thoughtleader: Life After Lipitor A conversation with a former Pfizer executive who "launched the world's best-selling drug." |
The Motley Fool
January 11, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Semiconductor Manufacturing International... Herbalife... New York & Company... Atherogenics... Hot Topic... |
The Motley Fool
December 28, 2005
Stephen D. Simpson |
AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either. |
Managed Care
March 2000 |
JAMA Study Challenges Key HEDIS Diabetes Measure How often should diabetic patients be screened for retinopathy? |
The Motley Fool
February 12, 2007
Bill Barker |
How to Win CNBC's Million-Dollar Challenge You can win -- but not with a sane investing strategy. AtheroGenics is a stock tailor-made for this game. |
The Motley Fool
October 25, 2005
Tim Beyers |
Who's Buying Now? Data management, heart drugs, and medicine for tots top this week's list of insider buys: Acxiom... AtheroGenics... ITT Educational Services... Natus Medical... Tessco Technologies... etc. |
The Motley Fool
February 1, 2008
Brian Lawler |
AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs. |
